bluuebunny/crossref_metadata_2025_split huggingface dataset:
Nonisolated high gain hybrid switched‐inductor DC‐DC converter with common switch grounding
Authors: Baba M. F. , Giridhar A. V. , Narasimharaju B. L. 
Published: April 2022

AbstractThis paper presents a methodology that integrates the hybrid switched inductor (HSL) and split duty ratio techniques to synthesize a high gain converter with common switch grounding (HSL‐CSG). The DC‐DC converter's high gain feature is required for microsource power processing in low voltage renewable energy systems. The amplification in voltage gain of the proposed converter is achieved without using transformer, common core coupled inductors, voltage multipliers, intermediate capacitors, and voltage lifting methods so that the topology is simple in construction and operation. Moreover, with a split duty ratio the proposed converter switches are less prone to current stress due to reduction in extreme conducting duty intervals. The topological derivation, operating principle, analysis of both continuous conduction mode (CCM), and discontinuous conduction mode (DCM) are presented. The theoretical analysis is validated with the aid of a laboratory prototype.
Cross‐sectional reassessment after 4 years of clinical routine use of AQUIOS CL for absolute T cell quantitation in a university hospital
Authors: Lemoine Léa , Malcus Christophe , Poitevin‐Later Françoise , Venet Fabienne , Monneret Guillaume , Gossez Morgane 
Published: April 2022

AbstractBackgroundWe had previously reported appropriate performances of automated AQUIOS CL cytometer (Beckman Coulter) for regulatory approval of absolute T cell enumeration. However, after 4 years of routine use, we still observed recurrent histogram anomalies that may affect both absolute values and T cell subset percentages results. The objective of the current study was thus to perform a cross‐sectional evaluation of these graphical anomalies within a university hospital context, to assess their influence on results and ultimately to propose a standardized decision tree to circumvent graphical disturbances at the time of results validation.MethodsEight hundred and sixty‐two blood samples were prospectively analyzed on AQUIOS CL. Results were compared to (i) lymphocyte values from complete blood count; (ii) results from manual staining and analysis on Navios cytometer (Beckman Coulter); (iii) results after washing step and reacquisition on AQUIOS CL.ResultsNearly 75% analyses did not show any graphical anomaly. 20% had single anomaly on “Lymphs (45)” or “Lymphs EV” regions influencing T cells percentages and requiring manual re‐gating of “CD3− capture” region. 5% showed concomitant “Lymphs EV” and “Lymphs (45)” anomalies influencing both T cell percentages and absolute counting and requiring additional staining and analysis on Navios. Finally, <1% presented with anomaly on “CD4/CD8” histogram or “CD3+ All” region, influencing both T cell percentages and absolute counting.ConclusionsAround 25% AQUIOS CL results were flawed due to gating anomalies. In <5% cases, additional back‐up procedures should be undertaken to ensure results validity. A simple decision‐tree may help in guiding validation process.
Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort
Authors: Chen Shiqun , Huang Zhidong , Liang Yan , Zhao Xiaoli , Aobuliksimu Xiemuxikaimaier , Wang Bo , He Yibo , Kang Yu , Huang Haozhang , Li Qiang , Yao Younan , Lu Xiaozhao , Qian Xiaoxian , Xie Xujing , Liu Jin , Liu Yong 
Published: April 2022

AbstractAimsAvailable evidence is incomplete and inconsistent in the outcomes of heart failure (HF) patients with preserved ejection fraction (HFpEF), mildly reduced ejection fraction (HFmrEF), and reduced ejection fraction (HFrEF). There are also limited data on the proportions and long‐term prognosis among the three HF phenotypes in China. We aimed to characterize the 5 year prognosis in three HF phenotypes according to EF in a cohort of hospitalized HF patients undergoing coronary angiography in southern China.Methods and resultsHospitalized patients with HF were enrolled from the Cardiorenal ImprovemeNt registry (CIN; ClinicalTrials.gov NCT04407936) between January 2007 and December 2014. HF phenotypes were defined as HFpEF (EF ≥ 50%), HFmrEF (EF 41–49%), and HFrEF (EF ≤ 40%). Kaplan–Meier and Cox proportional hazards models were constructed to examine differences in 5 year outcomes in HF patients with different phenotypes. A total of 4880 HF patients [mean age: 61.8 ± 10.3, male: 3156 (64.7%)] were included: 2768 (57%) had HFpEF, 1015 (21%) had HFmrEF, and 1097 (22%) had HFrEF. Patients with HFrEF were older than those with HFpEF (62.5 ± 10.6 vs. 61.3 ± 10.1, P < 0.001) and more likely to be male (78.0% vs. 55.9%, P < 0.001). With 5 year follow‐up through the end of December 2019, 1624 (27.6%) patients died. Controlling confounding variables, declined EF category was independently associated with increased 5 year mortality {HFrEF 25.2% vs. HFpEF 13.4%, adjusted hazard ratio [aHR]: 1.85 [95% confidence interval (CI): 1.45 to 2.35]; HFmrEF 18.1% vs. HFpEF 13.4%, aHR: 1.40 [95% CI: 1.08 to 1.81]; HFrEF 25.2% vs. HFmrEF 18.1%, aHR: 1.32 [95% CI: 1.02 to 1.71]}.ConclusionsIn this Chinese cohort, patients with HFrEF account for less than a fourth of HF patients. One‐sixth individuals with HF died in 5 years. HFrEF was associated with a nearly two‐fold increased risk of 5 year mortality than HFpEF. Further studies are needed to prospectively evaluate the efficacy of improving treatment on outcomes in all three HF phenotypes.
Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
Authors: Yang Liu , Zhang Min , Hao Zhiheng , Wang Nan , Zhang Min 
Published: April 2022

AbstractAimsRadiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long‐term recurrence rate of AF is still high. Sacubitril/valsartan (Sac/Val) is superior to valsartan in attenuating ventricular remodelling and improving clinical outcomes in heart failure patients, but whether this additional benefit exists in reversing atrial remodelling and reducing AF recurrence of RFCA‐treated AF patients remains uncovered.Methods and resultsPatients that had undergone RFCA were enrolled and randomly assigned 1:1 to valsartan (160 mg/day) or Sac/Val (200 mg/day) treatment group, in addition to other standard treatment of AF. Patients were followed up for 24 weeks. Echocardiography and ambulatory Holter monitoring for 24 h was performed at 24 weeks after RFCA. The primary end point was the change of atrial diameter from baseline to 24 weeks after RFCA. Second end points included the recurrence rate of AF, all‐cause hospitalization and all‐cause death. A total of 64 AF patients were enrolled, 32 of which received Sac/Val and 32 received valsartan treatment. There was no difference in the age (64.8 ± 9.8 vs. 63.7 ± 9.0, P = 0.634), gender (per cent of male: 59.4% vs. 50.0%, P = 0.616), heart rate (84.7 ± 4.1 b.p.m. vs. 80.9 ± 2.6 b.p.m., P = 0.428), systolic (127.5 ± 15.4 mmHg vs. 130.0 ± 17.8 mmHg, P = 0.549) or diastolic (81.7 ± 9.8 mmHg vs. 79.9 ± 12.6, P = 0.537) blood pressure upon admission between valsartan and Sac/Val treatment groups. The percentage of persistent AF was also comparable (43.8% vs. 53.1%, P = 0.617) in both treatment groups. Patients receiving Sac/Val treatment displayed significant decrease in the left atrial diameter (4.3 ± 0.5 cm to 3.8 ± 0.5 cm, P < 0.001), volume index (48.0 ± 6.4 mL/m2 to 41.7 ± 7.0 mL/m2, P < 0.001), and right atrial diameter (4.4 ± 0.8 cm to 3.9 ± 0.7 cm, P = 0.017) from baseline to 24 weeks after RFCA. This effect was not observed in valsartan treatment group. There was a numerical decrease in AF recurrence rate in the Sac/Val group compared with valsartan group (9.4% vs. 15.6%), although this difference did not reach a statistical significance (P = 0.708). No difference in all‐cause hospitalization rate (6.3% in each group) or all‐cause death rate (0% in each group) was observed.ConclusionsOur data indicate that Sac/Val is superior to valsartan in attenuating atrial structural remodelling in catheter ablation‐treated AF patients.
Simultaneous Determination of Gallic Acid and Folic Acid in Fruit Juice Samples Using Square Wave Voltammetry at Electrochemically Pretreated Carbon Paste Electrode
Authors: Tesfaye Gizaw , Negash Negussie , Hailu Tesfu , Tessema Merid 
Published: April 2022

AbstractAn efficient sensor was developed for the simultaneous determination of gallic and folic acid in juice samples using an electrochemically pretreated carbon paste electrode. The electrode was characterized by CV and EIS. The electrochemical behavior of GA and FA was evaluated by CV and SWV. The electrode exhibited high electrocatalytic activity towards GA and FA due to high surface area. Under the optimized condition, linear plots in the ranges of 0.08–13 μM and 0.1 to 15 μM were obtained for GA and FA, respectively. The proposed method was successful for the simultaneous determination of GA and FA in juice samples with satisfactory recovery.
Temporal evolution of headwall erosion rates derived from cosmogenic nuclide concentrations in the medial moraines of Glacier d'Otemma, Switzerland
Authors: Wetterauer Katharina , Scherler Dirk , Anderson Leif S. , Wittmann Hella 
Published: April 2022

AbstractClimate change affects the stability and erosion of high‐alpine rock walls above glaciers (headwalls) that deliver debris to glacier surfaces. Since supraglacial debris in the ablation zone alters the melt behaviour of the underlying ice, the responses of debris‐covered glaciers and of headwalls to climate change may be coupled. In this study, we analyse the beryllium‐10 (10Be)‐cosmogenic nuclide concentration history of glacial headwalls delivering debris to the Glacier d'Otemma in Switzerland. By systematic downglacier‐profile‐sampling of two parallel medial moraines, we assess changes in headwall erosion through time for small, well‐defined debris source areas. We compute apparent headwall erosion rates from10Be concentrations ([10Be]), measured in 15 amalgamated medial moraine debris samples. To estimate both the additional10Be production during glacial debris transport and the age of our samples we combine our field‐based data with a simple model that simulates downglacier debris trajectories. Furthermore, we evaluate additional grain size fractions for eight samples to test for stochastic mass wasting effects on [10Be]. Our results indicate that [10Be] along the medial moraines vary systematically with time and consistently for different grain sizes. [10Be] are higher for older debris, closer to the glacier terminus, and lower for younger debris, closer to the glacier head. Computed apparent headwall erosion rates vary between ~0.6 and 10.8 mm yr−1, increasing over a maximum time span of ~200 years towards the present. As ice cover retreats, newly exposed headwall surfaces may become susceptible to enhanced weathering and erosion, expand to lower elevations, and contribute formerly shielded bedrock of likely different [10Be]. Hence, we suggest that recently lower [10Be] reflect the deglaciation of the debris source areas since the end of the Little Ice Age.
Position‐sensitivity security transmission with orbital angular momentum directional modulation based on frequency diverse array
Authors: Zhu Changju , Song Maozhong , Dang Xiaoyu , Zhu Qiuming 
Published: April 2022

AbstractThe position‐sensitivity security communication scheme with orbital angular momentum (OAM) directional modulation (DM) beam pattern generated by the uniform circular frequency diverse array (FDA) is proposed. The transmitter employs FDA antennas to generate dual‐mode range‐dependent OAM beam and the direction information of OAM beam is modulated into the signal. The designed signal with random frequency offset excites the element of the uniform circular FDA to generate orthogonal OAM signals in the desired position. In the undesired position, the intensity pattern and the phase front of the radio beam vary randomly with the digital sequence transmission, which can make eavesdropping difficult. Since the modulation waveform has position‐dependent, the signal can be purposely distorted in undesired positions to provide transmission security for the legitimate user. The composite dual‐mode OAM signal makes it more difficult for eavesdroppers to demodulate correct messages. The receiver with a single antenna employs the phase compensation and helical phase factor to restore the correct digital signal in the desired position. Numerical results show that the space position‐sensitivity OAM‐DM technology based on FDA offers a security transmission scheme.
Brain co‐delivery of first‐line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy
Authors: Liu Yanjie , Wang Wendie , Zhang Dongya , Sun Yajing , Li Fangzhou , Zheng Meng , Lovejoy David B. , Zou Yan , Shi Bingyang 
Published: April 2022

AbstractGlioblastoma (GBM) is a central nervous system tumor with poor prognosis due to the rapid development of resistance to mono chemotherapy and poor brain targeted delivery. Chemoimmunotherapy (CIT) combines chemotherapy drugs with activators of innate immunity that hold great promise for GBM synergistic therapy. Herein, we chose temozolomide, TMZ, and the epigenetic bromodomain inhibitor, OTX015, and further co‐encapsulated them within our well‐established erythrocyte membrane camouflaged nanoparticle to yield ApoE peptide decorated biomimetic nanomedicine (ABNM@TMZ/OTX). Our nanoplatform successfully addressed the limitations in brain‐targeted drug co‐delivery, and simultaneously achieved multidimensional enhanced GBM synergistic CIT. In mice bearing orthotopic GL261 GBM, treatment with ABNM@TMZ/OTX resulted in marked tumor inhibition and greatly extended survival time with little side effects. The pronounced GBM treatment efficacy can be ascribed to three key factors: (i) improved nanoparticle‐mediated GBM targeting delivery of therapeutic agents by greatly enhanced blood circulation time and blood–brain barrier penetration; (ii) inhibited cellular DNA repair and enhanced TMZ sensitivity to tumor cells; (iii) enhanced anti‐tumor immune responses by inducing immunogenic cell death and inhibiting PD‐1/PD‐L1 conjugation leading to enhanced expression of CD4+ and CD8+ T cells. The study validated a biomimetic nanomedicine to yield a potential new treatment for GBM.
Dietary total antioxidant capacity and its association with renal function and kidney stones: Results of a RaNCD cohort study
Authors: Moludi Jalal , Tandorost Arash , Kamari Negin , Abdollahzad Hadi , Pakzad Reza , Najafi Farid , Pasdar Yahya 
Published: April 2022

AbstractThere is evidence to support the hypothesis that dietary antioxidants have shown protective effects against chronic kidney disease (CKD). The purpose of this study was to determine the association between the dietary total antioxidant capacity (DTAC), renal function, and development of CKD and kidney stones in Ravansar Non‐Communicable Diseases (RaNCD) cohort study, Kermanshah, Iran. This cross‐sectional study was conducted using the recruitment baseline data of the RaNCD cohort study on 9,777 individuals aged 35–65 years. Food frequency questionnaire (FFQ) was performed to assess diet. DTAC scores were calculated using the ferric reducing antioxidant power (FRAP) of selected foods. Renal function was assessed by the estimated glomerular filtration rate (eGFR), blood urea nitrogen, and serum creatinine concentration. Prevalent CKD was based on an eGFR less than <60 ml/min per 1.73 m2. Incidence of kidney stones was also assessed by self‐reporting. Out of 9,777 participants, 1,747 subjects (eGFR: 18.50 ml/min per 1.73 m2; 95% confidence interval (CI): 17.72–19.30) had CKD. The mean DTAC score in this study was 0.24 ± 0.16 µmol TE/100 g (micromole of Trolox Equivalents). We showed a significant trend for eGFR across quartiles of DTAC, i.e., participants in the fourth quartile had a higher glomerular filtration rate (GFR) than those in the first one (DTAC Q4 vs Q1 = 82.20 versus 72.20 ml/min per 1.73 m2, p < .001). Another finding is that high DTAC scores were not associated with having kidney stones after adjusting for confounders. We revealed that higher DTAC scores have positive effects on the renal function. Interestingly, our findings showed that a high DTAC score had nonsignificant correlation with odds of kidney stones.
The potential efficacy and mechanism of bendamustine in entra‐nodal NK/T cell lymphoma
Authors: Gao Yuyang , Feng Xiaoyan , Song Wenting , Li Hongwen , Shi Cunzhen , Jin Mengyuan , Li Zhaoming , Zhang Lei , Zhang Mingzhi 
Published: April 2022

AbstractBendamustine has been shown to have anti‐tumor activities in hematological malignancies, but the role of bendamustine in natural killer (NK)/T cell lymphoma (NKTCL) treatment is unclear. Our study has shown that bendamustine had potent growth‐inhibitory and apoptosis‐inducing effects on NKTCL cells. Interestingly, we noticed that the combination of either gemcitabine or etoposide results in additive or synergistic cytotoxicity. Bendamustine induced mitochondria‐mediated apoptosis in concentration‐ and time‐dependent manners in NKTCL cells, shown as down‐regulation of Bcl‐2 and activation of cleavage of caspases 3, 7, 9 and poly adenosinediphosphate‐ribose polymerase (PARP). Bendamustine arrested NKTCL cells in G2/M phase, with downregulation of expression of cyclin B1 and upregulation of expression of p‐cdc2, p‐cdc25c and p‐P53. Furthermore, we confirmed that bendamustine activated DNA damage response (DDR) directly or through Ataxia Telangiectasia Mutated Protein (ATM)/Chk2 and ATR/Chk1 pathway and increased the intracellular reactive oxygen species (ROS) level in NKTCL cells, which caused G2/M phase arrest and apoptosis. Bendamustine also inhibited phosphorylation of transcriptional factor STAT3, contributing to cell apoptosis and proliferation inhibition. Finally, we verified the effect of bendamustine on NKTCL cells in vivo. It showed that bendamustine dramatically inhibited the growth of the subcutaneous tumor, with no obvious impact on mice weight. These findings demonstrate that bendamustine activates DDR pathway, induces the accumulation of intracellularROS level as well as inhibition of STAT3, leading to cell apoptosis and G2/M cell cycle arrest in NKTCL cells, which indicates that bendamustine dramatically suppressed NKTCL both in vitro and in vivo and provides a potential therapeutic strategy in the treatment of NK/T lymphoma.
Mainstreaming resilience analytics: 10 years after the Fukushima disaster
Authors: Galaitsi Stephanie , Kurth Margaret , Fries Steffenie , Linkov Igor 
Published: April 2022

Abstract
Multiple events over the last decade, including the ongoing COVID-19 pandemic, demonstrate a global lack of preparedness for low probability but high consequence events. Following the evaluation of the Fukushima Daiichi nuclear disaster, these authors called for a change from a risk-oriented approach to a resilience-focused framework for managing such disruptions. Over the past five years, the field of resilience analytics has conceptualized further resilience frameworks within the context of infrastructure development; however, the practice of resilience planning is still lagging behind the theories developed in the literature. In this article, we consider the lessons learned from the Fukushima nuclear accident through the lens of newly developed resilience analytics and the ongoing COVID-19-related challenges. Integr Environ Assess Manag 2022;18:1551–1554. © 2022 SETAC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
KEY POINTS
The field of resilience analytics has conceptualized assessment frameworks for the context of infrastructure development; however, the practice of resilience planning is still lagging behind the theories developed in the literature. Resilience-by-design and resilience-by- intervention are two strategies that can help in achieving resilience in complex systems.
Effectiveness and safety of a microcrystalline tyrosine‐adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: A real‐life prospective observational study
Authors: Padró Clara , Gutiérrez Diego , Moreno Francisco , Parra Antonio , Rial Manuel J. , Lleonart Ramón , Torán‐Barona Carla , Justicia José L. , Roger Albert 
Published: April 2022

AbstractIntroductionAlthough clinical trials have shown the efficacy and safety of allergen‐specific immunotherapy (AIT) in the treatment of allergic asthma, there is a need for real‐life studies. We aimed to assess the effectiveness and safety of a microcrystalline tyrosine‐adjuvanted Dermatophagoides pteronyssinus allergoid (Acarovac Plus®) in patients with house dust mite (HDM)‐induced allergic asthma in a real‐life study.MethodsA subanalysis of a multicenter, prospective, observational, real‐life study. Patients with rhinitis and allergic asthma caused by HDMs were assessed before AIT with Acarovac Plus® and at 6 and 12 months after this treatment. Assessment parameters were percentage of days with asthma symptoms, percentage of days on asthma medication, classification of asthma according to Spanish guidelines for the management of asthma, asthma‐related quality of life (quality of life in adults with asthma questionnaire [QLAAQ]), perception of symptoms (visual analog scale [VAS]), and treatment satisfaction (treatment satisfaction questionnaire for medication [TSQM]). Safety was assessed by the number and severity of adverse reactions.ResultsThis subanalysis included 55 patients. Treatment with Acarovac Plus® showed significant differences in the analyzed variables when the baseline visit was compared with the 12‐month visit: reduction of the mean (SD) percentage of days with asthma symptoms (23.9 [9.2] vs. 5.1 [12.8]; p = .002), of the mean [SD] percentage of days on asthma medication (67.6 [42.9] vs. 45.1 [46.8]; p = .002), and of the percentage of patients with persistent asthma (78.2% vs. 38.9%; p = .009). Acarovac Plus® significantly improved asthma‐related quality of life, as shown by a decrease of 1.39 points in QLAAQ score at 12 months (p < .001), and in the subjective perception of symptoms on the VAS (−3.50, p < .0001). Patients showed high treatment satisfaction according to the TSQM, and it was well tolerated. No serious adverse events were reported.ConclusionsAcarovac Plus® was effective and safe for the treatment of patients with HDM‐induced allergic asthma in a real‐life study.